Durvalumab, a PD‐L1 inhibitor, was recently shown to be statistically non‐inferior to sorafenib in the phase III HIMALAYA trial in patients with HCC and Child‐Pugh A cirrhosis and FDA approval for durvalumab as a first‐line therapy option for HCC is anticipated.22 This evidence concerns the gene CD274 and hepatocellular carcinoma.